biostudies-literatureUnknown13(2)Duminuco A<h4>Background</h4>Immune system impairment is frequently reported in patients affected by hemoglobinopathies due to various mechanisms, including iron accumulation, antigenic stimulation due to numerous transfusions, chronic hemolysis, and a general hyperinflammatory state. For these reasons, the antigenic immune response after a vaccine risks being ineffective.<h4>Methods</h4>We evaluated the anti-spike IgG production after two doses of vaccine for SARS-CoV-2 in patients affected by hemoglobinopathies.<h4>Results</h4>All 114 enrolled patients (100%) developed adequate antibody production, with a median value of serum IgG of 2184.4 BAU/mL (IQR 1127.4-3502.9). The amount of antibody was unrelated to any other clinical characteristics evaluated, including transfusion dependence or non-transVaccines111https://www.ebi.ac.uk/biostudies/studies/S-EPMC11860232biostudies-literatureImmune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.PMC11860232Raimondo FDTibullo DRosso RBulla ALa Spina EDuminuco AXimenes BGiallongo CPalumbo GARomeo MARomano ACambria DfalseImmune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience.<h4>Background</h4>Immune system impairment is frequently reported in patients affected by hemoglobinopathies due to various mechanisms, including iron accumulation, antigenic stimulation due to numerous transfusions, chronic hemolysis, and a general hyperinflammatory state. For these reasons, the antigenic immune response after a vaccine risks being ineffective.<h4>Methods</h4>We evaluated the anti-spike IgG production after two doses of vaccine for SARS-CoV-2 in patients affected by hemoglobinopathies.<h4>Results</h4>All 114 enrolled patients (100%) developed adequate antibody production, with a median value of serum IgG of 2184.4 BAU/mL (IQR 1127.4-3502.9). The amount of antibody was unrelated to any other clinical characteristics evaluated, including transfusion dependence or non-trans2025-01-01T00:00:00Z2025 Jan2025-04-22T18:59:28.717Z2025-04-06T02:37:38.483ZS-EPMC118602324000665810.3390/vaccines13020111